Dynogen’s goal is to be a leading clinical stage pharmaceutical company focused on developing drugs to treat GI and GU diseases and disorders. Each disease area where the Company is focused represents a multi-billion dollar market opportunity due to a large and underserved patient population.

Today, Dynogen has three clinical stage products in various phases of development - DDP733, DDP225 and DDP200 - for four indications.

Gastrointestinal Pipeline: Positive Clinical Data

In 2007, Dynogen completed three of its proof of concept human clinical trials in its gastrointestinal pipeline. All three programs generated positive data:

• DDP733 for the treatment of irritable bowel syndrome with constipation (IBS-c). In February 2007, the Company announced positive results from its Phase 2a proof of concept trial of DDP733 in IBS-c. The Company initiated a Phase 2b study of DDP733 in patients with IBS-c in the fourth quarter of 2007.
• DDP225 for the treatment of irritable bowel syndrome with diarrhea (IBS-d). In December 2007, Dynogen announced positive results from its Phase 2a proof of concept trial of DDP225 in IBS-d. A Phase 2b study is planned.
• DDP733 for the treatment of nocturnal gastroesophageal reflux disease (NGERD). Dynogen announced positive results from its Phase 1b proof of concept study of DDP733 for the treatment of NGERD. A Phase 2 study is planned.

Genitourinary Pipeline: Clinical Development Programs

Dynogen has two product candidates in its genitourinary pipeline:

• DDP200 for the treatment of overactive bladder (OAB). The Company is planning a Phase 2b trial.
• DDP225 is ready for Phase 2 development as a treatment for the treatment of OAB.

The Dynogen Portfolio

In building a portfolio, Dynogen is increasing its likelihood for clinical success in the development process by focusing on product candidates with known safety and pharmacokinetic profiles, determined dose ranging, and evidence of efficacy. Dynogen’s current product candidate portfolio consists of drugs with a reduced development risk based on strong preclinical data and data obtained through human clinical studies.

The Company expects to identify and secure rights to additional product candidates that meet tie above criteria as part of its effort to build a promising pipeline based on products with potential new uses, new combinations, new dosages or new delivery approaches. This approach allows for a highly cost effective infrastructure with capital focused on multiple value-generating clinical programs.